{"as_of":"2026-08-08T09:10:00Z","caps":{"database_statements":6,"inbound":100,"outbound":100},"context_digest":"sha256:c6a2726bb3cd8160a6729a04991f1e2191edfc3ec1c7407ddb1557ba0ce3b1ad","coverage":[{"denominator":37,"lane":"reference_resolution","note":"Typed states for the displayed outbound observations.","records_observed":37,"source":"paper_references, paper_reference_links","source_observed_at":"2026-08-07T11:21:20.870837Z","state":"measured"},{"denominator":37,"lane":"standing_notices","note":"One-hop event checks from named stored sources.","records_observed":37,"source":"scholarly_work_events, retraction_status_cache","source_observed_at":"2026-08-08T06:32:00.761636+00:00","state":"measured"},{"denominator":0,"lane":"inbound_itemization","note":"Pith citing papers itemized under the disclosed page cap.","records_observed":0,"source":"paper_references, paper_reference_links","source_observed_at":null,"state":"measured"},{"denominator":1,"lane":"external_citation_measurements","note":"A source-named dated measurement, never combined with another source.","records_observed":0,"source":"cited_works","source_observed_at":null,"state":"measured"}],"external_citation_measurements":[],"inbound":[],"links":{"evidence":"/evidence","html":"/paper/2506.03050/citation-record","integrity":"/paper/2506.03050/integrity","json":"/paper/2506.03050/citation-record.json","paper":"/paper/2506.03050"},"outbound":[{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.155387Z","title":"://www.fda.gov/media/162416/download, available from: https://www.fda.gov/media/162416/download [Accessed 11th March 2024]","venue":null,"work_id":"4160fc42-df7b-41c9-b803-8ec179734eb4","year":2022},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":1,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.760372Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:e24bc5539bb1bdfe0205386292ebe94701026e69dc5c403f2d225fb5fa506486","observation_id":"3bc4a751-3e1c-489e-9251-023d0c860649","resolution":{"observed_at":"2026-08-07T11:21:21.158941Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.146098Z","title":"Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003;289(19):2554--2559","venue":null,"work_id":"e2eab173-6c64-43a9-9da8-d4f33620dc72","year":2003},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":2,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.764056Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:9834e9d25b8109758d95a67d0299a3a1469823ba70caf3389908e53a8d805505","observation_id":"3083a1ea-2fa8-45ed-8248-71e0ed6bf2ae","resolution":{"observed_at":"2026-08-07T11:21:21.150381Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.138457Z","title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","venue":null,"work_id":"18046f08-b247-453e-9e76-f0aff468a619","year":2012},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":3,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.767596Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:f9164d385c3fb6d29edc4861388ed348fe5345af9a5a505e31c70efad64f00ff","observation_id":"e44a426e-40a4-4a1e-b235-773071480b88","resolution":{"observed_at":"2026-08-07T11:21:21.141335Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.130338Z","title":"Generalized pairwise comparisons of prioritized outcomes in the two-sample problem","venue":null,"work_id":"67c477f6-24fb-48d1-bca9-0d57ac9c554b","year":2010},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":4,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.771355Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:e568d69d7a7f2bbb4895ef602cd2d7dd86a94eae9bb70d32ad60cb8fb859cc7b","observation_id":"983576df-1f5f-42ee-a29a-d9c0cbc65e5c","resolution":{"observed_at":"2026-08-07T11:21:21.133774Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.121978Z","title":"The win ratio: on interpretation and handling of ties","venue":null,"work_id":"9f53e746-8cb9-4350-99a5-979c87325309","year":2020},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":5,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.774560Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:7d36fd84f91f885007210cfefea214caa84d789e036684623258616218d0339e","observation_id":"5471d2ad-ed38-493f-a687-39098454b36e","resolution":{"observed_at":"2026-08-07T11:21:21.125650Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.113629Z","title":"Win odds: An adaptation of the win ratio to include ties","venue":null,"work_id":"29aa7384-c35d-4a59-a495-ba9f783d9698","year":2021},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":6,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.778160Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:0b5e6bc7a95b93304b24a52e4679e979238770b9dbcca15f082e899c5a0866f5","observation_id":"d92b2f11-25d4-4fd9-b064-a2027b83f8b8","resolution":{"observed_at":"2026-08-07T11:21:21.116338Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.106340Z","title":"An alternative approach to confidence interval estimation for the win ratio statistic","venue":null,"work_id":"714b5c12-8a2a-4904-be48-faee816c4f8b","year":2015},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":7,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.782049Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:78514002fce6c40a70313c57824c12db86eb4fa96d53770d0ca54945263e6e0d","observation_id":"c5d168da-d437-4a1b-8926-a39d28a053ca","resolution":{"observed_at":"2026-08-07T11:21:21.109123Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.098025Z","title":"Large sample inference for a win ratio analysis of a composite outcome based on prioritized components","venue":null,"work_id":"2e135d33-cee7-4f61-9e9b-2f2bcc1c6ffb","year":2016},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":8,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.785440Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:900a2fec28e87b1643e492493fc7c4b287183ea70534a17120ecb12571c74c4a","observation_id":"084d49e8-390b-43c9-9499-c4f48eeb49c3","resolution":{"observed_at":"2026-08-07T11:21:21.101073Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.091330Z","title":"On the win-ratio statistic in clinical trials with multiple types of event","venue":null,"work_id":"c93457c3-6ceb-4cb5-87fa-124c6a124bc0","year":2016},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":9,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.789634Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:22bcdb89990508d48380fd28d83fcabe4329125c0e8ee2fc6e8e714afc84d5e6","observation_id":"c0885589-9ac2-42ac-ae79-878fcd3f5ecc","resolution":{"observed_at":"2026-08-07T11:21:21.093818Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.084004Z","title":"Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial","venue":null,"work_id":"6dc046d8-c96a-48db-8ebb-1af45d5e6b66","year":2016},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":10,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.792100Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:dc27ce5de7eda861c27d2421afd281e6e4574e9342a5547215ff52b3b7a05e08","observation_id":"dd35fa49-2901-491e-ae05-6a803eb42e99","resolution":{"observed_at":"2026-08-07T11:21:21.086892Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.075763Z","title":null,"venue":null,"work_id":"d681ba48-e290-4cdb-af29-d97a527e03f9","year":2019},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":11,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.794901Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:b2f045aa5a0e90aa12588ef813aafa1c26492e91d41cae8b4375e52e3548af89","observation_id":"ec4d0641-658a-4a9e-b96a-2c2ef5b5419b","resolution":{"observed_at":"2026-08-07T11:21:21.078899Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.067911Z","title":"On recurrent-event win ratio","venue":null,"work_id":"cc84bb71-7b6c-49be-96d5-4969b461cb3d","year":2022},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":12,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.797672Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:683cac2b2c2df9b9f55b10862656afe5ebc0b45b08a5617330a68afdf229567c","observation_id":"97a53203-2c71-4542-b142-b2f2d63fee04","resolution":{"observed_at":"2026-08-07T11:21:21.070950Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.059890Z","title":"The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards","venue":null,"work_id":"fc9ba0aa-b46c-40d3-ba90-d2adb04e8a00","year":2020},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":13,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.800174Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:a15589699587cd12807c63f0def808de7a49209959e056c6fe8bd4611e7671c0","observation_id":"cf57e4b5-a40a-409f-9dcc-ac5c77a49630","resolution":{"observed_at":"2026-08-07T11:21:21.063073Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.051248Z","title":"The inverse-probability-of-censoring weighting ( IPCW ) adjusted win ratio statistic: An unbiased estimator in the presence of independent censoring","venue":null,"work_id":"16df5f0d-be75-421e-9696-39c4680e3b8e","year":2020},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":14,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.802592Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:6888bb5ca736437e96161b38767a01200c156a0b1e06bf9a832112a03b12b932","observation_id":"4dc118ed-2869-4d09-b376-df2e067e9378","resolution":{"observed_at":"2026-08-07T11:21:21.054427Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.042405Z","title":"Adjusting win statistics for dependent censoring","venue":null,"work_id":"9ff26cc8-ae8d-492c-a883-dbb812bb5f26","year":2021},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":15,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.805216Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:bad75ca9a1b833eca99e4ddc76d5e9ca87186e54767d76fc4fbf709fdcabf3ea","observation_id":"76722439-154c-4bfb-b91f-c1bfdfed1d96","resolution":{"observed_at":"2026-08-07T11:21:21.045764Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.033356Z","title":"Win-loss parameters for right-censored event data, with application to recurrent events","venue":null,"work_id":"2df66890-3b5c-4e7e-be7d-c0c3f41fd104","year":2023},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":16,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.807873Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:89eb15ed19aed3315665640aa16436a0b0999c613254f81e386f59b5b9b0363b","observation_id":"b318705a-edba-42e9-a60d-0522349af218","resolution":{"observed_at":"2026-08-07T11:21:21.036729Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.023018Z","title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","venue":null,"work_id":"db3e14bb-e04a-40f7-a900-0f456990e892","year":2014},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":17,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.810826Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:673c757ee438ec93244863d0387ca1e0b4dcd18511dd03690ba44cc65b244163","observation_id":"eb16dec3-b54a-4779-b1e4-d9be99d6eb0a","resolution":{"observed_at":"2026-08-07T11:21:21.026459Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.013707Z","title":"On the empirical choice of the time window for restricted mean survival time","venue":null,"work_id":"a9b98390-41d7-43d1-9195-4490bd95ec5b","year":2020},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":18,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.814033Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:c96721fd7f800b461546f2f15f9c5d9a1562b5919ab51ac7bca24b3e7974e874","observation_id":"562fd213-ee08-4d1b-b705-b7d59db14d16","resolution":{"observed_at":"2026-08-07T11:21:21.017225Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:21.004469Z","title":"Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments","venue":null,"work_id":"2ce427e5-db5d-489c-af97-1f6f218acd1a","year":2022},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":19,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.816848Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:180a29b8fa98da62798e7f979ec1e02d0a44d7beeb6eba17898ba5f6478292fb","observation_id":"e9f311dc-b9dc-4d69-8319-380a64f1c4c6","resolution":{"observed_at":"2026-08-07T11:21:21.008226Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.996382Z","title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","venue":null,"work_id":"5166360a-247a-4c09-abc3-b1f56b6e7dbc","year":2019},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":20,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.819350Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:044f0b545fcaf104a83cd2959d8a873b237aee33ff13a540ee350fda298ce43d","observation_id":"03d5ee6a-af30-4309-bb02-fb3562151482","resolution":{"observed_at":"2026-08-07T11:21:20.999518Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.985819Z","title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","venue":null,"work_id":"39a4f000-35a9-48a6-810a-6fbe5a5fd0cc","year":2020},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":21,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.822665Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:53422d8edae6f254fc57540c18e53cda7486f617a9c90cc7865ece4c141bba04","observation_id":"e001bcd1-51e5-4a47-b936-3d5e026fc4ab","resolution":{"observed_at":"2026-08-07T11:21:20.989142Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.976167Z","title":"When you look matters: the effect of assessment schedule on progression-free survival","venue":null,"work_id":"09a5ef9b-489d-4099-8570-f47a9a5a01e4","year":2007},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":22,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.825235Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:7b7f1984d3635b3bfdc40fdd7c9e0e1a4b3b0c71d748b799ec23b4739808ba42","observation_id":"8933dbfa-11e3-497f-bf42-124702b7b460","resolution":{"observed_at":"2026-08-07T11:21:20.978994Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.967320Z","title":"American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes","venue":null,"work_id":"95bd0159-18d4-437a-9ac6-dbdfccfe43bb","year":2014},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":23,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.827684Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:e75600b667f18ba8b90134fe65fb88b7f2d7bae8e04ef8fd83176884f7085aae","observation_id":"5aeb6b79-042e-4606-9cb9-bf9301f7648a","resolution":{"observed_at":"2026-08-07T11:21:20.970368Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.956054Z","title":"Treatment selections using risk--benefit profiles based on data from comparative randomized clinical trials with multiple endpoints","venue":null,"work_id":"d95db3f2-d86d-435e-bf01-5a2fd895ad32","year":2015},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":24,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.830671Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:aafbdcad91562e15d9483ec10d39c5d5b9c6744167c83bfc2fd577a3efb9613a","observation_id":"97114303-d106-4f09-a087-dc8ee7b171cb","resolution":{"observed_at":"2026-08-07T11:21:20.960672Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.945405Z","title":null,"venue":null,"work_id":"60532721-e604-4c3c-a393-55c978ce72b9","year":1991},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":25,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.833509Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:e782a6fecc20df23ecb40569feb256f576f2ca4cdb99a01028adcdce41d95c10","observation_id":"6f9a3c60-ae35-42d5-ae3f-7ef48b6b6175","resolution":{"observed_at":"2026-08-07T11:21:20.949729Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-08T06:32:00.761636+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.836226Z","title":"write newline","venue":null,"work_id":null,"year":null},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":26,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.836226Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:c319f5a134371c81023593780b78b4c080518f174b305d409e1a17b7ddf41d3b","observation_id":"4d0c1927-eacf-4b46-a408-ccc6bcf57078","resolution":{"observed_at":"2026-08-07T11:21:20.836226Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.839458Z","title":", \" * write output.state after.block = add.period write newline","venue":null,"work_id":null,"year":null},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":27,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.839458Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:d3788fc9cd61a52ab9d117579fa9af9b87194698bdf399acd4ca893624ef884a","observation_id":"df1ab362-b400-47a7-aa80-c5783cfeecd6","resolution":{"observed_at":"2026-08-07T11:21:20.839458Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.842807Z","title":"write newline","venue":null,"work_id":null,"year":null},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":28,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.842807Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:26b2c180e8b3ea08dcf4f9e7454d22ad061783c7f6837f89633897ef9980e713","observation_id":"7e0042b1-d871-4041-8249-68d0bcb6ee63","resolution":{"observed_at":"2026-08-07T11:21:20.842807Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.845780Z","title":"write newline","venue":null,"work_id":null,"year":null},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":29,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.845780Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:8f8a85f2c415affbb7a29d877cc6cc1ef3d3f5f0ff7ed9c065822955363de00e","observation_id":"c931f794-8abf-46e6-8e37-93cb34e16883","resolution":{"observed_at":"2026-08-07T11:21:20.845780Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.848655Z","title":"write newline","venue":null,"work_id":null,"year":null},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":30,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.848655Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:0c7590f303a213042e2b53b19f421c08e6717952c74b8220dbda9ae6e2c149ff","observation_id":"d05b341c-4a74-4f9b-988f-07f858f8a15d","resolution":{"observed_at":"2026-08-07T11:21:20.848655Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.851928Z","title":"write newline","venue":null,"work_id":null,"year":null},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":31,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.851928Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:40a4caaa5b70a5c3aefb086d0a32fb9165df9f75ab59e62e428be633ec01f31f","observation_id":"8e62d2bc-194b-42f9-9b04-fe96b677f207","resolution":{"observed_at":"2026-08-07T11:21:20.851928Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.855947Z","title":", \" * write output.state after.block = add.period write newline","venue":null,"work_id":null,"year":null},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":32,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.855947Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:a721b73e4873e2e61b1e21465944e246d205f143a435a198d74d4536cf6b435c","observation_id":"dc9d6f14-17d6-44db-aeec-743a159c078b","resolution":{"observed_at":"2026-08-07T11:21:20.855947Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.859373Z","title":"write newline","venue":null,"work_id":null,"year":null},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":33,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.859373Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:a35b87acc4edfe96c74d1c1eca16a664e63471aa42ca7d84bcb815eaad4dfa03","observation_id":"02fa08af-0fdb-4352-b321-716ff9688b2d","resolution":{"observed_at":"2026-08-07T11:21:20.859373Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.862106Z","title":"write newline","venue":null,"work_id":null,"year":null},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":34,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.862106Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:5ad5213f79ec67d77e5a3e07f6c1834c065aee4beb34a1f664d6eb67fa914f50","observation_id":"6466451d-66f5-4dfa-ab7c-3cc6e3caf4fb","resolution":{"observed_at":"2026-08-07T11:21:20.862106Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.864966Z","title":"write newline","venue":null,"work_id":null,"year":null},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":35,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.864966Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:302000bfdda9e73984c61b8c24de9bd82572e91e0b7b9eeeac33021efaa46c5f","observation_id":"de63131d-f549-4f22-b9e6-3a27246d20cb","resolution":{"observed_at":"2026-08-07T11:21:20.864966Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.868059Z","title":"Available from:","venue":null,"work_id":null,"year":null},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":36,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.868059Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:5c97b8511f3e43875014a8f6f22003991e9fcbcd2a3e59ca3bfe97ec3cf51eb3","observation_id":"88573247-5cee-4e99-8c39-833e4302d03c","resolution":{"observed_at":"2026-08-07T11:21:20.868059Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-07T11:21:20.870837Z","title":"write newline","venue":null,"work_id":null,"year":null},"citing_paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties","version":1},"reference_index":37,"source":"arxiv_source","source_observed_at":"2026-08-07T11:21:20.870837Z"},"links":{"citing_paper":"/paper/2506.03050"},"observation_digest":"sha256:7c12924e5939d87e8aefc5b3edbc7fba0f6dc5ec05405d97e4e73efd5e3f0111","observation_id":"e4280ba1-09a2-4519-b71e-659f3556e57c","resolution":{"observed_at":"2026-08-07T11:21:20.870837Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}}],"paper":{"arxiv_id":"2506.03050","last_updated":"2025-06-03T16:30:45Z","latest_version":1,"primary_category":"stat.ME","snapshot_observed_at":"2026-08-07T11:07:16.996538Z","submitted_at":"2025-06-03T16:30:45Z","title":"An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties"},"reference_resolution":{"displayed":37,"state_counts":{"malformed_identifier":0,"metadata_mismatch":0,"parse_uncertain":0,"unresolved":14,"verified_exact":0,"verified_fuzzy":23},"total_outbound_references":37},"refusal":"A citation records a reference. It does not transfer a finding from one paper to another.","schema":"pith.paper-citation-record.v1","standing_sources":[{"observed_at":"2026-08-08T06:32:00.761636+00:00","source":"crossref"},{"observed_at":"2026-08-08T06:31:55.24221+00:00","source":"retraction_watch"}],"thesis":"As of 8 August 2026, this Paper Citation Record lists 37 of 37 outbound references and 0 inbound Pith citation observations for arXiv:2506.03050."}